Literature DB >> 11008877

Age-related changes of MAO-A and -B distribution in human and mouse brain.

N Mahy1, N Andrés, C Andrade, J Saura.   

Abstract

Age-related changes of MAO-A and -B were studied in human and BL/C57 mouse brain areas (substantia nigra, putamen and cerebellum). [3H]Ro41-1049 and [3H]lazabemide were used as selective radioligands to image and quantify MAO-A and MAO-B respectively by enzyme autoradiography. MAO-A binding was higher in mouse, whereas MAO-B binding was higher in human. With aging, mouse MAO-A was significantly reduced between 4 and 8 weeks and remained unchanged until 19 months followed by a slight increase between 19 and 25 months. In contrast, no clear variation was observed in humans between the age of 17-93 years. In most of the structures studied a clear age-related increase in MAO-B was observed beginning in mouse brain at 4 weeks, whereas in human tissue this increase started at the age of 50-60 years. These results show marked differences in the levels and variations of mouse and human MAO-A and -B associated with aging and should be taken into account when extrapolating experimental data from mouse to human.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11008877

Source DB:  PubMed          Journal:  Neurobiology (Bp)        ISSN: 1216-8068


  11 in total

Review 1.  Astrocytes and therapeutics for Parkinson's disease.

Authors:  Phillip M Rappold; Kim Tieu
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

2.  Dual monoamine oxidase B and acetylcholine esterase inhibitors for treating movement and cognition deficits in a C. elegans model of Parkinson's disease.

Authors:  Jacob Boos; Ahmed Shubbar; Werner J Geldenhuys
Journal:  Med Chem Res       Date:  2021-04-09       Impact factor: 2.351

3.  α-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's disease.

Authors:  Seong Su Kang; Eun Hee Ahn; Zhentao Zhang; Xia Liu; Fredric P Manfredsson; Ivette M Sandoval; Susov Dhakal; P Michael Iuvone; Xuebing Cao; Keqiang Ye
Journal:  EMBO J       Date:  2018-05-16       Impact factor: 11.598

4.  C/EBPβ/δ-secretase signaling mediates Parkinson's disease pathogenesis via regulating transcription and proteolytic cleavage of α-synuclein and MAOB.

Authors:  Zhourui Wu; Yiyuan Xia; Zhihao Wang; Seong Su Kang; Kecheng Lei; Xia Liu; Lingjing Jin; Xiaochuan Wang; Liming Cheng; Keqiang Ye
Journal:  Mol Psychiatry       Date:  2020-02-21       Impact factor: 15.992

5.  Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's disorders?

Authors:  Moussa B H Youdim
Journal:  Rambam Maimonides Med J       Date:  2010-10-31

6.  Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's diseases as disease modifying agents.

Authors:  Moussa B H Youdim
Journal:  Exp Neurobiol       Date:  2010-06-30       Impact factor: 3.261

7.  Baicalin Represses C/EBPβ via Its Antioxidative Effect in Parkinson's Disease.

Authors:  Kecheng Lei; Yijue Shen; Yijing He; Liwen Zhang; Jingxing Zhang; Weifang Tong; Yichun Xu; Lingjing Jin
Journal:  Oxid Med Cell Longev       Date:  2020-05-21       Impact factor: 6.543

Review 8.  Understanding the Multiple Role of Mitochondria in Parkinson's Disease and Related Disorders: Lesson From Genetics and Protein-Interaction Network.

Authors:  Valentina Nicoletti; Giovanni Palermo; Eleonora Del Prete; Michelangelo Mancuso; Roberto Ceravolo
Journal:  Front Cell Dev Biol       Date:  2021-04-01

Review 9.  Revisiting the Role of Astrocytic MAOB in Parkinson's Disease.

Authors:  Min-Ho Nam; Moonsun Sa; Yeon Ha Ju; Mingu Gordon Park; C Justin Lee
Journal:  Int J Mol Sci       Date:  2022-04-18       Impact factor: 6.208

10.  Age-related behavioral phenotype of an astrocytic monoamine oxidase-B transgenic mouse model of Parkinson's disease.

Authors:  Christopher A Lieu; Shankar J Chinta; Anand Rane; Julie K Andersen
Journal:  PLoS One       Date:  2013-01-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.